首页> 美国卫生研究院文献>MedChemComm >The synthesis biological evaluation and structure–activity relationship of 2-phenylaminomethylene-cyclohexane-13-diones as specific anti-tuberculosis agents
【2h】

The synthesis biological evaluation and structure–activity relationship of 2-phenylaminomethylene-cyclohexane-13-diones as specific anti-tuberculosis agents

机译:2-苯基氨基亚甲基-环己烷-13-二酮作为抗结核剂的合成生物学评价及构效关系

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The present study utilised whole cell based phenotypic screening of thousands of diverse small molecules against Mycobacterium tuberculosis H37Rv (M. tuberculosis) and identified the cyclohexane-1,3-dione-based structures >5 and >6 as hits. The selected hit molecules were used for further synthesis and a library of 37 compounds under four families was synthesized for lead generation. Evaluation of the library against M. tuberculosis lead to the identification of three lead antituberculosis agents (>37, >39 and >41). The most potential compound, 2-(((2-hydroxyphenyl)amino)methylene)-5,5-dimethylcyclohexane-1,3-dione (>39) showed an MIC of 2.5 μg mL–1, which falls in the range of MICs values found for the known antituberculosis drugs ethambutol, streptomycin and levofloxacin. Additionally, this compound proved to be non-toxic (<20% inhibition at 50 μM concentration) against four human cell lines. Like first line antituberculosis drugs (isoniazid, rifampicin and pyrazinamide) this compound lacks activity against general Gram positive and Gram negative bacteria and even against M. smegmatis; thereby reflecting its highly specific antituberculosis activity.
机译:本研究利用基于全细胞的表型筛选了数千种针对结核分枝杆菌H37Rv(结核分枝杆菌)的小分子,并确定了基于环己烷-1,3-二酮的结构> 5 和> 6 。选定的命中分子用于进一步合成,并合成了四个家族下的37种化合物的文库以产生先导。评估针对结核分枝杆菌的文库可鉴定出三种主要抗结核药(> 37 ,> 39 和> 41 )。最有潜力的化合物2-((((2-羟苯基)氨基)亚甲基)-5,5-二甲基环己烷-1,3-二酮(> 39 )的MIC为2.5μgmL –1 ,该值在已知抗结核药乙胺丁醇,链霉素和左氧氟沙星的MIC值范围内。此外,该化合物被证明对四种人类细胞系无毒(在50μM浓度下抑制率<20%)。像一线抗结核药(异烟肼,利福平和吡嗪酰胺)一样,该化合物对一般革兰氏阳性和革兰氏阴性细菌甚至对耻垢分枝杆菌均​​无活性。从而反映其高度特异性的抗结核活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号